Kaiser Permanente Southern California's population-based program for men with prostate cancer has led to improved outcomes, according to a study published in Urology Practice.
A comprehensive, population-based regional healthcare management program for men with prostate cancer who are members of Kaiser Permanente Southern California has led to improved outcomes, according to a Kaiser Permanente study published in Urology Practice.
Kaiser Permanente Southern California developed the prostate cancer care program in 2003. It is focused on screening and prevention, shared decision making for treatment following diagnosis and care improvement for men with localized and advanced disease.
Related:Cancer management demands evidence-based treatment
“The program is designed to span the continuum of care and is primarily focused on screening and prevention, shared decision making for treatment following diagnosis and care improvement for men with localized and advanced disease,” says author Ronald K. Loo, MD, regional chief of urology, Southern California Permanente Medical Group. “We wanted to see if managing prostate cancer as a chronic condition would favorably impact patient satisfaction and clinical outcome. What we found was that the program resulted in improved quality and better outcomes for these prostate cancer patients.”
Specifically, the improvements made to the healthcare delivery model include:
“The program is designed to span the continuum of care and is primarily focused on screening and prevention, shared decision making for treatment following diagnosis and care improvement for men with localized and advanced disease,” says study author Ronald K. Loo, MD, regional chief of urology, Southern California Permanente Medical Group. “We wanted to see if managing prostate cancer as a chronic condition would favorably impact patient satisfaction and clinical outcome. What we found was that the program resulted in improved quality and better outcomes for these prostate cancer patients.
NEXT: "Providing safe, reliable, cost-effective and evidence-based care to all members afflicted with prostate cancer.."
LooIn addition, before Dr. Loo and colleagues began their work, many patients were receiving expensive chemotherapy medications with unreliable oversight. Medications utilization was unknown.
“Outcome from medication dispensing was unknown, and side effects and complications from these medications was never properly addressed,” Dr. Loo says. “As the result of our work, survival has improved, side effects have diminished, costs have significantly reduced, and iatrogenic complications are significantly improved.”
As an example, because a particular chemotherapy [leuprolide] is known to worsen bone demineralization, according to Dr. Loo, standardized intense screening and treatment for osteoporosis in this population has resulted in a >70% reduction in hip fractures, “saving needless suffering and countless lives. Medication mismanagement is one of the most costly and wasteful processes that requires careful control,” he says.
“We are focused on providing safe, reliable, cost-effective and evidence-based care to all members afflicted with prostate cancer, irrespective of where they live, or with whom they seek their care,” Dr. Loo continues. “To do so across a relatively wide geographic region, developing evidence-based recommendations and protocols for management is only part of the solution.”
Leveraging its integrated healthcare delivery model by hard-wiring these recommendations and protocols is where Kaiser has achieved most of our recent success, according to Dr. Loo.
Related:HHS awards $110 million for delivery system reform
“Because our entire healthcare delivery team actively participates in analyzing external and internal evidence, and helps formulate our protocols for management, we achieve remarkable compliance because everyone owns the model,” he says. “We have realized millions of dollars in cost savings as a by-product of this quality improvement work, not as a primary goal.”
The program that was put in place in 2003 initially as a case management program to manage advanced cancer patients who received clinic administered chemotherapy. As additional subpopulations within the prostate cancer umbrella were identified, the program expanded to improve the spectrum of care related to prostate cancer addressed screening, shared decision-making for treatment following diagnosis and care improvement for men with localized disease who elect to undergo robotic surgery.
“These were implemented with traditional quality improvement techniques and outcomes were evaluated in collaboration with research groups embedded within the organization,” Dr. Loo says. “We now cover almost the entire spectrum of prostate cancer management and have transferred this process to other conditions and applications.”
Dr. Loo believes that other healthcare providers and organizations may wish to adopt aspects of this program, as clinicians treating men with prostate cancer aim to provide the highest quality, affordable care.
Related:WellPoint initiative aims to identify cancer treatment therapies
“A fully integrated healthcare delivery model is not mandatory to adopt many of our successful processes, but it does require close collaboration and interdependence,” he says.
“Encourage your clinical care delivery teams to look for ways to deliver reliable, reproducible, evidence-based care,” Dr. Loo advises. “Furthermore, the stakeholders who deliver this care must own the process, otherwise they will never be fully invested or accountable. Improve the reliability and quality first, and the cost savings will follow accordingly.”
How the Contact Center Can Be a Driver of VBC Success
December 23rd 2024Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for conveying information to patients and plan members. Today, however, AI-enabled contact centers can be drivers of value, especially in a value-based care environment.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen